盐酸氨基葡萄糖片治疗尿毒症膝骨关节炎的疗效及安全性分析

The efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis

目的观察盐酸氨基葡萄糖片治疗尿毒症患者膝骨关节炎的疗效及安全性。方法选择2015年2月—6月确诊患膝骨关节炎的尿毒症患者118例,随机分为盐酸氨基葡萄糖片组(治疗组)、包醛氧淀粉胶囊组(对照组),每组各59例,疗程均为8周。采用Lequesne功能演算指数作为疗效评定指标,分别于治疗前与治疗第8周后比较治疗前后膝关节休息痛、运动痛、压痛、肿胀、晨僵和行走能力的改善情况;及治疗前后患者透析充分性、血电解质、肝功能、肾功能的变化,对药物安全性进行评价。结果治疗组患者Lequesne评分总有效率为72.9%,优于对照组的13.6%(χ~2=42.303,P<0.001)。两组患者的透析充分性、血常规、血电解质及肝肾功能在治疗前后均无明显变化(P>0.05)。结论盐酸氨基葡萄糖片治疗尿毒症患者膝骨关节炎的疗效和安全性较好。

Objective To observe the treatment efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis （OA）. Methods A total of 118 uremia patients with knee OA were selected and randomly divided into the glucosamine hydrochloride tablets treatment group （treatment group） and the coated aldehyde oxystarch capsules group （control group） with 59 cases in each group. The course was 8 weeks. The Lequesne Index was assessed for curative effect evaluation, and the change of blood indexes was observed to evaluate drug safety. Results The total effective rate of Lequesne Index in the treatment group was 72.9%, while that in the control group was 13.6%; the difference was statistically significant （X2=42.303, P〈0.001）. There was no significant change in the two groups before and after treatment in terms of the patients＇ dialysis adequacy, routine blood, blood electrolytes, liver and kidney function （P〉0.05）.Conclusion Glucosamine hydrochloride tablets is curative and safe in the treatment of uremia patients with OA.